A four-chemokine signature is associated with a T cell-inflamed phenotype in primary and metastatic pancreatic cancer.

CONCLUSIONS: A conserved 4-chemokine signature marks resectable and metastatic PDAC tumors with an active antitumor phenotype. This could have implications for the appropriate selection of PDAC patients in immunotherapy trials.
PMID: 31964786 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 20, 2020 Category: Cancer & Oncology Authors: Romero JM, Grünwald BT, Jang GH, Bavi PP, Jhaveri A, Masoomian M, Fischer SE, Zhang A, Denroche RE, Lungu IM, De Luca A, Bartlett JMS, Xu J, Li N, Dhaliwal S, Liang SB, Chadwick D, Vyas F, Bronsert P, Khokha R, McGaha TL, Notta F, Ohashi PS, Done SJ, O'K Tags: Clin Cancer Res Source Type: research